solid tumours

Oncology

CAR-NK cell therapies for solid tumours: Closing the gap bet...

CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.

Oncology

pharmaphorum podcast Episode 222, Lew Bender, Intensity Therapeutics

Delving into the physics of cancer, with Lew Bender

In a new podcast, Intensity Therapeutics' Lew Bender discusses intra-tumourally injected therapeutics - a novel approach to cancer cell death.

Oncology

The mesenchymal stem cell’s superpower: Hacking the TME

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this shield.

News

Martin Olin has been named chief executive of the UK start-up

UK biotech Swarm lands with a T-cell therapy mission

UK firm Swarm Oncology launches with a T-cell therapy platform to treat solid tumours, with a Resolution Therapeutics co-founder in the pilot seat.

News

CARsgen gets a win for CAR-T in solid tumours

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satri-cel has shown efficacy in gastric cancer, setting up a filing in China.

News

ArsenalBio raises $325m for programmable CAR-T platform

Arsenal Biosciences has cleared an impressive $325 million from a third-round financing that will be used to fund clinical trials of its pipeline of CAR-T therapies, trying to break new gro

CAR-NK cell therapies for solid tumours: Closing the gap bet...

Delving into the physics of cancer, with Lew Bender

The mesenchymal stem cell’s superpower: Hacking the TME

UK biotech Swarm lands with a T-cell therapy mission

CARsgen gets a win for CAR-T in solid tumours

ArsenalBio raises $325m for programmable CAR-T platform

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

solid tumours

Editor's Picks